These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37971319)

  • 1. Tumor immune evasion: insights from CRISPR screens and future directions.
    Djajawi TM; Wichmann J; Vervoort SJ; Kearney CJ
    FEBS J; 2024 Apr; 291(7):1386-1399. PubMed ID: 37971319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor immunology CRISPR screening: present, past, and future.
    Dong MB; Tang K; Zhou X; Zhou JJ; Chen S
    Trends Cancer; 2022 Mar; 8(3):210-225. PubMed ID: 34920978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo CRISPR screens identify
    Feng X; Yang C; Huang Y; Su D; Wang C; Wilson LL; Yin L; Tang M; Li S; Chen Z; Zhu D; Wang S; Zhang S; Zhang J; Zhang H; Nie L; Huang M; Park JI; Hart T; Jiang D; Jiang K; Chen J
    Proc Natl Acad Sci U S A; 2024 Sep; 121(39):e2406325121. PubMed ID: 39298484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
    Potts MA; McDonald JA; Sutherland KD; Herold MJ
    Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-content CRISPR screening in tumor immunology.
    Holcomb EA; Pearson AN; Jungles KM; Tate A; James J; Jiang L; Huber AK; Green MD
    Front Immunol; 2022; 13():1041451. PubMed ID: 36479127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.
    Yim S; Hwang W; Han N; Lee D
    Front Immunol; 2022; 13():884561. PubMed ID: 35651625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancements in CRISPR screens for the development of cancer immunotherapy strategies.
    Li YR; Lyu Z; Tian Y; Fang Y; Zhu Y; Chen Y; Yang L
    Mol Ther Oncolytics; 2023 Dec; 31():100733. PubMed ID: 37876793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets.
    Noorani I; Bradley A; de la Rosa J
    Genome Biol; 2020 Aug; 21(1):204. PubMed ID: 32811551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies.
    Xiang M; Li H; Zhan Y; Ma D; Gao Q; Fang Y
    Mol Cancer; 2024 Apr; 23(1):73. PubMed ID: 38581063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.
    Dubrot J; Du PP; Lane-Reticker SK; Kessler EA; Muscato AJ; Mehta A; Freeman SS; Allen PM; Olander KE; Ockerman KM; Wolfe CH; Wiesmann F; Knudsen NH; Tsao HW; Iracheta-Vellve A; Schneider EM; Rivera-Rosario AN; Kohnle IC; Pope HW; Ayer A; Mishra G; Zimmer MD; Kim SY; Mahapatra A; Ebrahimi-Nik H; Frederick DT; Boland GM; Haining WN; Root DE; Doench JG; Hacohen N; Yates KB; Manguso RT
    Nat Immunol; 2022 Oct; 23(10):1495-1506. PubMed ID: 36151395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Cancer Immunotherapy with CRISPR-Based Technology.
    Li Z; Fei T
    Adv Biosyst; 2020 Nov; 4(11):e1900253. PubMed ID: 33245213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrogating immune cells and cancer with CRISPR-Cas9.
    Buquicchio FA; Satpathy AT
    Trends Immunol; 2021 May; 42(5):432-446. PubMed ID: 33812776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Immunotherapy: Diverse Approaches and Obstacles.
    Sanatkar SA; Heidari A; Rezaei N
    Curr Pharm Des; 2022; 28(29):2387-2403. PubMed ID: 35909273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy.
    Chen C; Wang Z; Qin Y
    Exp Hematol Oncol; 2023 Nov; 12(1):95. PubMed ID: 37964355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
    Hou J; Wang Y; Shi L; Chen Y; Xu C; Saeedi A; Pan K; Bohat R; Egan NA; McKenzie JA; Mbofung RM; Williams LJ; Yang Z; Sun M; Liang X; Rodon Ahnert J; Varadarajan N; Yee C; Chen Y; Hwu P; Peng W
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered CRISPR Systems for Next Generation Gene Therapies.
    Pineda M; Moghadam F; Ebrahimkhani MR; Kiani S
    ACS Synth Biol; 2017 Sep; 6(9):1614-1626. PubMed ID: 28558198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.
    Wang X; Tokheim C; Gu SS; Wang B; Tang Q; Li Y; Traugh N; Zeng Z; Zhang Y; Li Z; Zhang B; Fu J; Xiao T; Li W; Meyer CA; Chu J; Jiang P; Cejas P; Lim K; Long H; Brown M; Liu XS
    Cell; 2021 Oct; 184(21):5357-5374.e22. PubMed ID: 34582788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.
    Freeman AJ; Vervoort SJ; Ramsbottom KM; Kelly MJ; Michie J; Pijpers L; Johnstone RW; Kearney CJ; Oliaro J
    Cell Rep; 2019 Sep; 28(11):2784-2794.e5. PubMed ID: 31509742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics and immunotherapy: The current state of play.
    Dunn J; Rao S
    Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.